Advanced renal cell carcinoma of a histological or cytological confirmation of clear cell (or with a component of clear cell) renal carcinoma that have previously progressed on or were intolerant to first-line therapy with sunitinib, sorafenib, pazopanib, axitinib, bevacizumab, or cytokine therapy.

Prior nephrectomy (partial or total)

Patients with at least one measurable lesion at baseline as per the RECIST 1.0 criteria

Karnofsky Performance Status ≥ 70%

Exclusion Criteria:

Patients who have received more than one prior treatment regimen for metastatic renal-cell carcinoma